Literature DB >> 28059444

TNF-α promotes osteoclastogenesis through JNK signaling-dependent induction of Semaphorin3D expression in estrogen-deficiency induced osteoporosis.

Chenglin Sang1,2, Jiefeng Zhang3, Yongxian Zhang1,2, Fangjing Chen1,2, Xuecheng Cao1,2, Lei Guo4.   

Abstract

Tumor necrosis factor α (TNF-α)-induced osteoclast formation have been demonstrated to play an important role in the pathogenesis of estrogen deficiency-mediated bone loss, but the exact mechanisms by which TNF-α enhanced osteoclast differentiation were not fully elucidated. The class III semaphorins members were critical to regulate bone homeostasis. Here, we identified a novel mechanism whereby TNF-α increasing Semaphorin3D expression contributes to estrogen deficiency-induced osteoporosis. In this study, we found that Semaphorin3D expression was upregulated by TNF-α during the process of RANKL-induced osteoclast differentiation. Inhibition of Semaphorin3D in pre-osteoclasts could attenuate the stimulatory effects of TNF-α on osteoclast proliferation and differentiation. Mechanistically, blocking of the Jun N-terminal kinase (JNK) signaling markedly rescued TNF-α-induced Semaphorin3D expression, suggesting that JNK signaling was involved in the regulation of Semaphorin3D expression by TNF-α. In addition, silencing of Semaphorin3D in vivo could alleviate estrogen deficiency-induced osteoporosis. Our results revealed a novel function for Semaphorin3D and suggested that increased Semaphorin3D may contribute to enhanced bone loss by increased TNF-α in estrogen deficiency-induced osteoporosis. Thus, Semaphorin3D may provide a potential therapeutic target for the treatment of estrogen-deficiency induced osteoporosis.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  JNK signaling; Osteoclastogenesis; Semaphorin3D; TNF-α; proliferation

Mesh:

Substances:

Year:  2017        PMID: 28059444     DOI: 10.1002/jcp.25784

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

1.  Corilagin suppresses RANKL-induced osteoclastogenesis and inhibits oestrogen deficiency-induced bone loss via the NF-κB and PI3K/AKT signalling pathways.

Authors:  Jinwei Lu; Chenyi Ye; Yanyong Huang; Donghui Huang; Lan Tang; Weiduo Hou; Zhihui Kuang; Yazhou Chen; Shining Xiao; Mumingjiang Yishake; Rongxin He
Journal:  J Cell Mol Med       Date:  2020-07-18       Impact factor: 5.310

2.  Elevated lncRNA MIAT in peripheral blood mononuclear cells contributes to post-menopausal osteoporosis.

Authors:  Rui Li; Ting-Ting Shi; Qiang Wang; Yong-Xian Zhang
Journal:  Aging (Albany NY)       Date:  2022-04-05       Impact factor: 5.682

3.  Systems pharmacology dissection of action mechanisms for herbs in osteoporosis treatment.

Authors:  Ying Huai; Wen-Juan Zhang; Wei Wang; Kai Dang; Shan-Feng Jiang; Dan-Ming Li; Meng Li; Qiang Hao; Zhi-Ping Miao; Yu Li; Ai-Rong Qian
Journal:  Chin Herb Med       Date:  2021-06-03

Review 4.  Roles of Mitogen-Activated Protein Kinases in Osteoclast Biology.

Authors:  Kyunghee Lee; Incheol Seo; Mun Hwan Choi; Daewon Jeong
Journal:  Int J Mol Sci       Date:  2018-10-01       Impact factor: 5.923

Review 5.  Osteoimmunology: The Regulatory Roles of T Lymphocytes in Osteoporosis.

Authors:  Wenjuan Zhang; Kai Dang; Ying Huai; Airong Qian
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-11       Impact factor: 5.555

Review 6.  The Pathophysiology of Osteoporosis after Spinal Cord Injury.

Authors:  Ramsha Shams; Kelsey P Drasites; Vandana Zaman; Denise Matzelle; Donald C Shields; Dena P Garner; Christopher J Sole; Azizul Haque; Narendra L Banik
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.